Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

BACKGROUND: In Canada, two vaccines that have demonstrated high efficacy against infection with human papillomavirus (HPV) types −16 and −18 are available. The HPV-6/11/16/18 vaccine provides protection against genital warts (GW) while the HPV-16/18 vaccine may provide better protection against othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohli, Michele, Lawrence, Donna, Haig, Jennifer, Anonychuk, Andrea, Demarteau, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503751/
https://www.ncbi.nlm.nih.gov/pubmed/23061913
http://dx.doi.org/10.1186/1471-2458-12-872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503751/
https://www.ncbi.nlm.nih.gov/pubmed/23061913
http://dx.doi.org/10.1186/1471-2458-12-872

Ejemplares similares